Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy ...

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The ...

Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. According to ...

Medicare Advantage should be one of the best solutions for American health policy woes. It keeps costs in check and allows patients the freedom to choose providers they like. Washington needs to ...

Nick Madrigal's first foray into the shortstop position did not go as planned. The Mets infielder suffered a dislocated left shoulder on a slow roller on the infield grass during the first inning of ...